急性細菌性皮膚・皮膚構造感染症市場規模：感染タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域範囲別および予測

急性細菌性皮膚・皮膚構造感染症（ABSSSI）の市場規模・予測

急性細菌性皮膚・皮膚構造感染症（ABSSSI）の市場規模は、2024年に114億9,000万米ドルと評価され、2026年から2032年にかけてCAGR 9.6%で成長し、2032年には239億4,000万米ドルに達すると予測されます。

急性細菌性皮膚・皮膚構造感染症（ABSSSI）は、皮膚とその下の軟部組織の重症細菌感染症で、抗生物質で直ちに治療しなければならないです。蜂窩織炎、丹毒、重度の皮膚膿瘍、創傷感染などが含まれます。

ABSSSIは一般的にグラム陽性菌、特にメチシリン耐性黄色ブドウ球菌（MRSA）などのブドウ球菌やレンサ球菌によって引き起こされます。効果的な治療が行われない場合、これらの感染症は、患部の発赤、腫脹、不快感、温感などの症状により、重篤な罹患率を引き起こす可能性があります。

世界の急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場力学

急性細菌性皮膚・皮膚構造感染症市場を形成している主な市場力学は以下の通りです：

主な市場促進要因

皮膚・軟部組織感染症の有病率の増加：皮膚・軟部組織感染症、特にABSSSIの頻度増加は、この市場の主要促進要因です。米国疾病予防管理センター（CDC）によると、2015年の米国における皮膚・軟部組織感染症の外来受診者数は約1,420万人でした。この高い有病率は、ABSSSIに対する治療法の改善が急務であることを浮き彫りにしています。

抗生物質耐性の増加：抗生物質耐性菌に対する懸念の高まりは、ABSSSIに対する新たな治療法の開発を後押ししています。世界保健機関（WHO）によると、抗生物質耐性菌感染による死者は2019年に120万人を超えました。この懸念すべき事態が、ABSSSIに対する新薬と治療オプションの必要性を後押ししています。

ヘルスケア支出の増加：世界のヘルスケア支出の増加がABSSSI市場を後押ししています。世界銀行によると、GDPに占める世界の医療費の割合は2000年の8.5%から2019年には9.8%に増加しています。このようなヘルスケア投資の増加は、特に裕福な国々において、ABSSSIのような病気に対する治療法へのアクセスを向上させています。

主な課題

高い開発コスト：新規のABSSSI治療薬や治療法を生み出すには、多額の研究開発投資が必要です。この技術には高いコストがかかるため、製薬会社はこの分野への投資を躊躇し、製品の入手可能性とイノベーションを制限しています。

限られた治療選択肢：効果的なABSSSI治療に対する需要が高まっているにもかかわらず、認可された治療薬はわずかしかないです。アクセス可能な治療選択肢が少ないため、患者の選択肢が制限され、市場の急成長が阻害されます。

抗生物質耐性：抗生物質耐性菌がますます一般的になり、ABSSSIを効果的に治療することが難しくなっています。このため、現在の抗生物質の有効性が低下する一方で、開発が困難で時間のかかる革新的な治療オプションに対する需要が高まっています。

主な動向

認知度と有病率の高まり：ABSSSIの有病率に対する認識の高まりと発生率の上昇が市場を牽引しています。この動向は、特に免疫不全患者や慢性疾患を患う人々の間で皮膚・軟部組織感染症が増加していることに起因しています。

治療法の進歩：診断と治療技術の技術的進歩がABSSSI市場を変革しています。高度な画像診断技術と迅速な診断検査が早期発見を促し、タイムリーな介入と患者の転帰改善をもたらしています。

製薬企業による研究開発への取り組み：製薬会社は研究開発にますます力を入れています。これには、抗生物質耐性株を標的とした新規薬剤や治療法の開発が含まれ、これまで満たされていなかった医療ニーズに応えています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場：感染タイプ別

• 院内感染型ABSSSI
• 市中感染型ABSSSI

第5章 急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場：薬剤タイプ別

• 経口抗生物質
• 局所抗生物質

第6章 急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場：投与経路別

• 経口
• 経腸外投与
• 局所

第7章 急性細菌性皮膚・皮膚構造感染症（ABSSSI）市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第8章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第9章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第10章 競合情勢

• 主要企業
• 市場シェア分析

第11章 企業プロファイル

• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd
• Bayer AG
• GlaxoSmithKline plc
• Sanofi S.A.
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics, Inc.

第12章 市場展望市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第13章 付録

• 略語リスト
• 出典と参考文献

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Size and Forecast

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market size was valued at USD 11.49 Billion in 2024 and is projected to reach USD 23.94 Billion by 2032, growing at a CAGR of 9.6% from 2026 to 2032.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are severe bacterial infections of the skin and underlying soft tissues that must be treated immediately with antibiotics. They include cellulitis, erysipelas, severe cutaneous abscesses, and wound infections.

ABSSSIs are typically caused by Gram-positive bacteria, particularly Staphylococcus and Streptococcus species, such as methicillin-resistant Staphylococcus aureus (MRSA). If not treated effectively, these infections can cause severe morbidity, with symptoms including redness, swelling, discomfort, and warmth at the affected site.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Dynamics

The key market dynamics that are shaping the acute bacterial skin and skin structure infection market include:

Key Market Drivers

Increasing Prevalence of Skin and Soft Tissue Infections: The increased frequency of skin and soft tissue infections, especially ABSSSIs, is a major driver of this market. According to the US Centers for Disease Control and Prevention (CDC), there were approximately 14.2 million outpatient consultations for skin and soft tissue infections in the United States in 2015. This high prevalence highlights the urgent need for improved therapies for ABSSSI.

Rising Antibiotic Resistance: The growing concern about antibiotic-resistant bacteria is pushing the development of new treatments for ABSSSI. According to the World Health Organization (WHO), antibiotic-resistant bacterial infections killed more than 1.2 million people in 2019. This concerning development is driving the need for new medicines and treatment options for ABSSSIs.

Increasing Healthcare Expenditure: The global increase in healthcare spending is boosting the ABSSSI market. According to the World Bank, worldwide health expenditure as a proportion of GDP increased from 8.5% in 2000 to 9.8% in 2019. This increased healthcare investment is improving access to therapies for illnesses such as ABSSSIs, especially in wealthy countries.

Key Challenges:

High Development Costs: Significant research and development investments are required to create novel ABSSSI medicines and therapies. The high costs of this technique deter pharmaceutical companies from investing in this field, restricting product availability and innovation.

Limited Treatment Options: Despite the increasing demand for effective ABSSSI treatments, there are just a few authorized medications available. The scarcity of accessible treatment choices limits patient options and inhibits the market from growing as quickly as it can.

Antibiotic Resistance: Antibiotic-resistant bacterial strains are becoming increasingly common, making it difficult to treat ABSSSIs effectively. This diminishes the efficacy of current antibiotics while increasing the demand for innovative therapeutic options, which are difficult and time-consuming to develop.

Key Trends:

Growing Awareness and Prevalence: The market is being driven by increased awareness of the prevalence of ABSSSI, as well as rising incidence rates. This trend is caused by an increase in skin and soft tissue infections, particularly among immunocompromised people and those suffering from chronic conditions.

Advancements in Treatment Options: Technological advances in diagnoses and treatment techniques are transforming the ABSSSIs market. Advanced imaging techniques and speedy diagnostic tests promote early detection, resulting in timely interventions and better patient outcomes.

R&D Initiatives by Pharmaceutical Companies: Pharmaceutical companies are increasingly focusing on R&D. This includes the creation of novel medications and therapy targeted to antibiotic-resistant strains, thereby meeting previously unmet medical requirements.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Regional Analysis

Here is a more detailed regional analysis of the acute bacterial skin and skin structure infection market:

North America:

According to Verified Market Research, North America is estimated to dominate the acute bacterial skin and skin structure infection market over the forecast period. Skin and soft tissue infections, including ABSSSIs, are common in North America, especially in the United States. In 2014, the United States Centers for Disease Control and Prevention (CDC) reported roughly 3.4 million emergency department visits for skin and soft tissue infections. This high prevalence increases the demand for ABSSSI therapies in the region.

North America has a well-developed healthcare system and high healthcare spending, which allows for improved detection and treatment of ABSSSIs. According to the Centers for Medicare and Medicaid Services, healthcare spending in the United States increased by 4.6% in 2019, to USD 3.8 Trillion, or $11,582 per person. This level of spending encourages the use of newer, more effective therapies for ABSSSI.

Furthermore, MRSA is a common cause of ABSSSIs, and its presence in North America serves as a substantial market driver. The CDC estimates that approximately 2% of the population has MRSA. In 2017, there were around 323,700 cases of MRSA in hospitalized patients in the United States. This high occurrence of antibiotic-resistant illnesses necessitates the development of sophisticated ABSSSI treatments in the region.

Europe:

Europe region is estimated to exhibit substantial growth during the forecast period. Europe has a high incidence of skin and soft tissue infections, particularly ABSSSIs. According to the European Centre for Disease Prevention and Control (ECDC), surgical site infections, a kind of ABSSSI, were reported in 3.2% of surgical procedures in Europe in 2019. This high prevalence increases the demand for effective therapies in the region.

The increasing prevalence of antibiotic-resistant bacteria in Europe is driving the discovery and implementation of innovative treatments for ABSSSIs. According to the ECDC, over 33,000 persons in the EU/EEA died as a result of antibiotic-resistant bacterial illnesses in 2019. Methicillin-resistant Staphylococcus aureus (MRSA), a prevalent cause of ABSSSIs, is still a major public health concern, with MRSA accounting for more than 25% of Staphylococcus aureus isolates in seven of the 29 countries studied.

Furthermore, the aging of Europe's population, as well as the rise of chronic diseases, help to drive the ABSSSI market forward. According to Eurostat, the proportion of people aged 65 and up in the EU is expected to rise from 20.3% in 2019 to 29.4% in 2050. ABSSSIs are more likely to affect older persons and those with chronic diseases such as diabetes. According to the International Diabetes Federation, 59 million adults in Europe had diabetes in 2019, and this figure is anticipated to climb to 68 million by 2045, thereby increasing the incidence of ABSSSIs.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia Pacific region has a large population, which naturally results in a higher incidence of ABSSSI cases. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's population is predicted to increase from 4.3 billion in 2020 to 4.7 billion in 2050. This population increase translates to a larger patient pool for ABSSSIs, which drives market growth.

Diabetes poses a considerable risk for skin infections, especially ABSSSIs. According to the International Diabetes Federation (IDF), the number of adults living with diabetes in the Western Pacific region (which includes much of Asia) is anticipated to rise from 163 million in 2019 to 212 million by 2045. The rising prevalence of diabetes is anticipated to contribute to an increased incidence of ABSSSIs in the region.

Furthermore, the Asia Pacific region is rapidly improving its healthcare infrastructure and access. According to the World Health Organization (WHO), health expenditure as a proportion of GDP in Southeast Asia rose from 3.5% in 2000 to 4.4% in 2017. Improved healthcare spending and infrastructure development are improving diagnostic and treatment capabilities for illnesses such as ABSSSIs, resulting in market growth.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market: Segmentation Analysis

The Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market is segmented based on Infection Type, Drug Type, Route of Administration, Distribution Channel, and Geography.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Infection Type

• Hospital-acquired ABSSSI
• Community-acquired ABSSSI

Based on Infection Type, the market is segmented into Hospital-acquired ABSSSI and Community-acquired ABSSSI. The hospital-acquired ABSSSI segment is estimated to dominate the acute bacterial skin and skin structure infection market due to the high incidence of hospital-acquired ABSSSI cases caused by variables such as impaired skin integrity, the presence of multi-drug resistance organisms in healthcare settings, and immunosuppressed patients' susceptibility to severe infections.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Drug Type

• Oral & Parental Antibiotics
• Topical Antibiotics

Based on Drug Type, the market is segmented into Oral & Parental Antibiotics and Parental Antibiotics. The oral & parental antibiotics segment is estimated to dominate the acute bacterial skin and skin structure infection market during the forecast period owing to their great efficiency against a wide spectrum of bacterial illnesses and convenience of administration via the oral route. Parenteral antibiotics are especially important in severe cases because they provide increased bioavailability and tissue penetration, which is critical for treating illnesses such as bacteremia and sepsis.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Route of Administration

• Oral
• Parental
• Topical

Based on the Route of Administration, the market is segmented into Oral, Parental, and Topical. The parental segment is estimated to dominate the acute bacterial skin and skin structure infection market because parenteral antibiotics can quickly enter the bloodstream and successfully battle severe ABSSSI cases. The parenteral method is preferable for its quick drug administration and tailored treatment approach, particularly in urgent ABSSSI cases requiring prompt action.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Based on the Distribution Channel, the market is segmented into Hospital, Retail, Online, and Others. The hospital pharmacies segment is estimated to dominate the acute bacterial skin and skin structure infection market. Hospital pharmacies play an important role in ABSSSI therapy because they provide prompt access to essential medicines and work closely with healthcare teams to develop antibiotic regimens. Furthermore, hospital pharmacies help patients make a smooth transition to outpatient care by giving drugs upon release, assuring thorough and efficient ABSSSI therapy.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the acute bacterial skin and skin structure infection market is classified into North America, Europe, Asia Pacific, and the Rest of the World. According to the VMR analyst, North America is estimated to dominate during the forecasted period due to leading pharmaceutical companies' substantial research operations, a focus on creating anti-MRSA medications, and the introduction of new products. North America's market revenue is predicted to remain dominant due to the region's robust healthcare infrastructure and widespread awareness of ABSSSIs.

Key Players

• The "Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Inc., Merck & Co., Inc., AstraZeneca plc, Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Paratek Pharmaceuticals, Inc., and Melinta Therapeutics, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Acute Bacterial Skin and Skin Structure Infection Market Recent Developments
• In July 2021, Melinta Therapeutics, a pharmaceutical firm, released KIMYRSA, as a lipoglycopeptide antibiotic efficacious for treating acute bacterial skin and skin structure infections (ABSSSI) in a single 1200mg injectable dose.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Type of Infection

• Hospital-acquired ABSSSI
• Community-acquired ABSSSI

5. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Drug Type

• Oral & Parenteral Antibiotics
• Topical Antibiotics

6. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Route of Administration

• Oral
• Parenteral
• Topical

7. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

8. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

9. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

10. Competitive Landscape

• Key Players
• Market Share Analysis

11. Company Profiles

• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd
• Bayer AG
• GlaxoSmithKline plc
• Sanofi S.A.
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics, Inc.

12. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

13. Appendix

• List of Abbreviations
• Sources and References